Articles with public access mandates - Paul BarrLearn more
Not available anywhere: 3
Nivolumab plus brentuximab vedotin for relapsed/refractory primary mediastinal large B‐cell lymphoma: extended follow‐up from the phase 2 checkmate 436 study
PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, ...
Hematological Oncology 39, 2021
Mandates: Canadian Cancer Society
Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma
S Jahangiri, J Friedberg, P Barr
Expert opinion on emerging drugs 19 (3), 367-383, 2014
Mandates: Lymphoma Research Foundation, USA
Diffuse Large B-Cell Lymphoma in the Very Elderly: The Case for Refining Our Clinical Trials
PM Barr
Oncology 27 (2), 140, 2013
Mandates: Lymphoma Research Foundation, USA
Available somewhere: 81
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ...
New England Journal of Medicine 371 (3), 213-223, 2014
Mandates: US National Institutes of Health
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ...
New England Journal of Medicine 373 (25), 2425-2437, 2015
Mandates: US National Institutes of Health
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
WH Wilson, RM Young, R Schmitz, Y Yang, S Pittaluga, G Wright, CJ Lih, ...
Nature medicine 21 (8), 922-926, 2015
Mandates: US National Institutes of Health
Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ...
New England Journal of Medicine 379 (26), 2517-2528, 2018
Mandates: US National Institutes of Health
Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia
TD Shanafelt, XV Wang, NE Kay, CA Hanson, S O’Brien, J Barrientos, ...
New England Journal of Medicine 381 (5), 432-443, 2019
Mandates: US National Institutes of Health
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ...
Leukemia 34 (3), 787-798, 2020
Mandates: US National Institutes of Health
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ...
American journal of hematology 94 (12), 1353-1363, 2019
Mandates: US National Institutes of Health
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ...
The lancet oncology 19 (1), 65-75, 2018
Mandates: US National Institutes of Health
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ...
Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020
Mandates: US National Institutes of Health, National Institute for Health Research, UK
US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest …
OW Press, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, ...
Journal of Clinical Oncology 34 (17), 2020-2027, 2016
Mandates: US National Institutes of Health
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ...
Leukemia 32 (1), 83-91, 2018
Mandates: US National Institutes of Health
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ...
Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019
Mandates: US National Institutes of Health
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
V Jurinovic, R Kridel, AM Staiger, M Szczepanowski, H Horn, MH Dreyling, ...
Blood, The Journal of the American Society of Hematology 128 (8), 1112-1120, 2016
Mandates: US National Institutes of Health, German Research Foundation
Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study
PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, ...
Journal of Clinical Oncology 37 (33), 3081-3089, 2019
Mandates: US National Institutes of Health
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ...
Haematologica 103 (9), 1511, 2018
Mandates: US National Institutes of Health
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
PM Barr, GB Saylors, SE Spurgeon, BD Cheson, DR Greenwald, ...
Blood, The Journal of the American Society of Hematology 127 (20), 2411-2415, 2016
Mandates: Lymphoma Research Foundation, USA
Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
TD Shanafelt, XV Wang, CA Hanson, EM Paietta, S O’Brien, J Barrientos, ...
Blood, The Journal of the American Society of Hematology 140 (2), 112-120, 2022
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program